DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History
MIAMI, April 21, 2025 -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company").
Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value.
In DOMA Perpetual's view, the announced initiatives reflect Pacira's robust financial position and the Board's commitment to disciplined capital allocation. The combination of the $300 million dollar share repurchase program and a new emphasis on increasing margins at the pre-tax net income level is anticipated to strengthen shareholder returnii. The onus now falls on management to effectively execute these important initiatives.
"After engaging in conversations with representatives of the Company's Board and management team, we are encouraged by the clear steps Pacira is taking to drive long-term value creation," said Pedro Escudero, CEO and CIO of DOMA Perpetual. "We believe Pacira has entered a period of rapid growth; the new capital allocation priorities reflect the Company's considerable momentum as it continues scaling earnings and free cash flow, enabling it to return meaningful capital to shareholders while still investing in growth. It is our conviction the stock is undervalued relative to its historical average valuation and, more importantly, relative to the multiyear cycle of growth ahead."
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
